South San Francisco, California, March 16, 2026
Veracyte, Inc. announced the appointment of Kevin Haas, Ph.D., as Chief Development and Technology Officer, a newly created executive role aimed at accelerating the company’s global diagnostic product development strategy and precision medicine innovation. The appointment reflects Veracyte’s continued expansion in genomic diagnostics, bioinformatics, and AI-driven healthcare solutions, as the company strengthens its pipeline of advanced cancer diagnostic tests.
Strengthening End-to-End Diagnostic Development Capabilities
In his new role, Dr. Haas will oversee end-to-end product development, including diagnostic assay development, software engineering, and bioinformatics integration, ensuring seamless coordination across Veracyte’s innovation pipeline. His leadership will support the development of high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products, enabling the company to deliver clinically actionable insights for cancer diagnosis and management. With over 15 years of experience in life sciences technology, data science, and molecular diagnostics,
Dr. Haas brings expertise in building scalable diagnostic platforms and AI-enabled analytics systems, which are critical for advancing next-generation healthcare solutions. His appointment highlights Veracyte’s focus on integrating technology, genomics, and digital health capabilities to enhance diagnostic accuracy and clinical utility.
Driving Innovation in Multi-Omics and Precision Medicine
Advertisement
Veracyte’s growing pipeline includes expansion into whole-genome minimal residual disease (MRD) testing and multi-omics applications, requiring advanced capabilities in genomics, data analytics, and artificial intelligence. Dr. Haas will lead efforts to unify these technologies into a cohesive development framework, enabling the company to deliver innovative diagnostic solutions across the continuum of cancer care—from early detection to disease monitoring.
His prior experience in leading precision medicine platforms and digital health strategies will support Veracyte’s mission to provide high-value genomic insights that guide clinical decision-making. By leveraging AI-driven bioinformatics and large-scale genomic data, Veracyte aims to accelerate innovation and improve outcomes for patients facing complex diseases such as cancer.
Expanding Global Impact Through Technology and Data Integration
The appointment also underscores Veracyte’s commitment to building a globally scalable diagnostics platform powered by advanced informatics, automation, and data-driven technologies. The company’s diagnostic solutions are designed to integrate clinical, genomic, and molecular data, enabling more precise and personalized treatment strategies. By strengthening its leadership in AI-enabled diagnostics and laboratory innovation, Veracyte is positioning itself at the forefront of the evolving precision healthcare landscape.
The company continues to invest in research, development, and global commercialization efforts, ensuring that its diagnostic tools meet the highest standards of quality, regulatory compliance, and clinical performance. As the demand for personalized medicine and advanced diagnostic technologies continues to grow, Veracyte’s strategic leadership expansion is expected to play a key role in shaping the future of cancer care.
Source: Veracyte press release
